Neurocrine Historical Balance Sheet

NBIX Stock

USD 112.89 1.11 0.97%

Trend analysis of Neurocrine Biosciences balance sheet accounts such as Total Current Liabilities of 533.1 M provides information on Neurocrine Biosciences' total assets, liabilities, and equity, which is the actual value of Neurocrine Biosciences to its prevalent stockholders. By breaking down trends over time using Neurocrine Biosciences balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Neurocrine Biosciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Neurocrine Biosciences is a good buy for the upcoming year.

Neurocrine Biosciences Inventory

60.27 Million

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurocrine Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.

About Neurocrine Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Neurocrine Biosciences at a specified time, usually calculated after every quarter, six months, or one year. Neurocrine Biosciences Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Neurocrine Biosciences and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Neurocrine currently owns. An asset can also be divided into two categories, current and non-current.

Neurocrine Biosciences Balance Sheet Chart

At this time, Neurocrine Biosciences' Non Currrent Assets Other are fairly stable compared to the past year. Cash And Short Term Investments is likely to rise to about 1.1 B in 2025, whereas Cash is likely to drop slightly above 136.2 M in 2025.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Add Fundamental

Total Assets

Total assets refers to the total amount of Neurocrine Biosciences assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Neurocrine Biosciences books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Neurocrine Biosciences balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Neurocrine Biosciences are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Neurocrine Biosciences' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Neurocrine Biosciences current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurocrine Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.At this time, Neurocrine Biosciences' Non Currrent Assets Other are fairly stable compared to the past year. Cash And Short Term Investments is likely to rise to about 1.1 B in 2025, whereas Cash is likely to drop slightly above 136.2 M in 2025.

	2022	2023	2024	2025 (projected)
Short and Long Term Debt Total	262.9M	428.4M	455.1M	477.9M
Total Assets	2.4B	3.3B	3.7B	3.9B

Short Long Term Debt Total Total Assets

Neurocrine Biosciences balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Short Term Investments	Other Liab	Other Assets
Total Assets		0.22	0.98	0.87	0.99	0.94	0.47	0.62	0.99	0.41	0.99	0.74	0.95	0.98	0.48	0.82	0.69	0.92	0.97	0.93	0.99	0.58	0.87	0.94	0.29	0.77
Short Long Term Debt Total	0.22		0.2	0.39	0.16	0.21	0.4	-0.43	0.24	0.08	0.2	0.13	0.33	0.15	0.58	0.22	0.4	0.46	0.35	0.2	0.25	0.62	0.12	0.32	0.23	0.06
Other Current Liab	0.98	0.2		0.91	0.98	0.93	0.47	0.7	0.99	0.34	0.97	0.72	0.9	0.99	0.4	0.7	0.7	0.86	0.92	0.92	0.96	0.64	0.87	0.9	0.25	0.76
Total Current Liabilities	0.87	0.39	0.91		0.85	0.77	0.63	0.49	0.92	0.27	0.84	0.5	0.87	0.89	0.48	0.53	0.84	0.81	0.88	0.76	0.89	0.85	0.77	0.89	0.27	0.61
Total Stockholder Equity	0.99	0.16	0.98	0.85		0.95	0.42	0.67	0.98	0.38	0.99	0.76	0.93	0.99	0.44	0.78	0.64	0.9	0.93	0.94	0.97	0.54	0.86	0.92	0.29	0.78
Property Plant And Equipment Net	0.94	0.21	0.93	0.77	0.95		0.45	0.71	0.94	0.22	0.97	0.91	0.82	0.94	0.27	0.78	0.65	0.8	0.89	1.0	0.89	0.56	0.74	0.84	0.3	0.66
Net Debt	0.47	0.4	0.47	0.63	0.42	0.45		0.13	0.5	-0.34	0.45	0.37	0.48	0.47	0.25	0.35	0.81	0.47	0.56	0.45	0.49	0.76	0.22	0.48	0.42	-0.1
Retained Earnings	0.62	-0.43	0.7	0.49	0.67	0.71	0.13		0.67	0.04	0.68	0.64	0.39	0.7	-0.28	0.35	0.34	0.28	0.48	0.72	0.54	0.18	0.57	0.45	0.02	0.5
Accounts Payable	0.99	0.24	0.99	0.92	0.98	0.94	0.5	0.67		0.33	0.98	0.72	0.91	0.99	0.43	0.74	0.73	0.88	0.95	0.93	0.97	0.65	0.85	0.92	0.29	0.74
Cash	0.41	0.08	0.34	0.27	0.38	0.22	-0.34	0.04	0.33		0.36	0.01	0.53	0.31	0.52	0.53	0.1	0.48	0.45	0.2	0.46	0.0	0.62	0.47	-0.25	0.83
Non Current Assets Total	0.99	0.2	0.97	0.84	0.99	0.97	0.45	0.68	0.98	0.36		0.79	0.9	0.97	0.4	0.82	0.66	0.88	0.95	0.96	0.95	0.54	0.85	0.89	0.26	0.75
Non Currrent Assets Other	0.74	0.13	0.72	0.5	0.76	0.91	0.37	0.64	0.72	0.01	0.79		0.59	0.75	0.06	0.68	0.49	0.6	0.67	0.91	0.67	0.41	0.5	0.63	0.32	0.44
Cash And Short Term Investments	0.95	0.33	0.9	0.87	0.93	0.82	0.48	0.39	0.91	0.53	0.9	0.59		0.91	0.66	0.81	0.71	0.97	0.96	0.8	0.98	0.62	0.85	0.98	0.32	0.78
Net Receivables	0.98	0.15	0.99	0.89	0.99	0.94	0.47	0.7	0.99	0.31	0.97	0.75	0.91		0.41	0.72	0.67	0.87	0.92	0.93	0.97	0.59	0.84	0.92	0.34	0.73
Common Stock Shares Outstanding	0.48	0.58	0.4	0.48	0.44	0.27	0.25	-0.28	0.43	0.52	0.4	0.06	0.66	0.41		0.45	0.29	0.74	0.53	0.25	0.55	0.37	0.44	0.59	0.36	0.44
Non Current Liabilities Total	0.82	0.22	0.7	0.53	0.78	0.78	0.35	0.35	0.74	0.53	0.82	0.68	0.81	0.72	0.45		0.54	0.8	0.87	0.77	0.8	0.3	0.71	0.75	0.21	0.68
Other Current Assets	0.69	0.4	0.7	0.84	0.64	0.65	0.81	0.34	0.73	0.1	0.66	0.49	0.71	0.67	0.29	0.54		0.62	0.79	0.64	0.72	0.9	0.51	0.76	0.17	0.36
Other Stockholder Equity	0.92	0.46	0.86	0.81	0.9	0.8	0.47	0.28	0.88	0.48	0.88	0.6	0.97	0.87	0.74	0.8	0.62		0.92	0.79	0.94	0.59	0.78	0.93	0.37	0.71
Total Liab	0.97	0.35	0.92	0.88	0.93	0.89	0.56	0.48	0.95	0.45	0.95	0.67	0.96	0.92	0.53	0.87	0.79	0.92		0.88	0.97	0.66	0.84	0.94	0.27	0.74
Property Plant And Equipment Gross	0.93	0.2	0.92	0.76	0.94	1.0	0.45	0.72	0.93	0.2	0.96	0.91	0.8	0.93	0.25	0.77	0.64	0.79	0.88		0.87	0.54	0.72	0.83	0.32	0.64
Total Current Assets	0.99	0.25	0.96	0.89	0.97	0.89	0.49	0.54	0.97	0.46	0.95	0.67	0.98	0.97	0.55	0.8	0.72	0.94	0.97	0.87		0.62	0.87	0.97	0.32	0.78
Short Term Debt	0.58	0.62	0.64	0.85	0.54	0.56	0.76	0.18	0.65	0.0	0.54	0.41	0.62	0.59	0.37	0.3	0.9	0.59	0.66	0.54	0.62		0.4	0.68	0.22	0.25
Intangible Assets	0.87	0.12	0.87	0.77	0.86	0.74	0.22	0.57	0.85	0.62	0.85	0.5	0.85	0.84	0.44	0.71	0.51	0.78	0.84	0.72	0.87	0.4		0.81	0.16	0.89
Short Term Investments	0.94	0.32	0.9	0.89	0.92	0.84	0.48	0.45	0.92	0.47	0.89	0.63	0.98	0.92	0.59	0.75	0.76	0.93	0.94	0.83	0.97	0.68	0.81		0.34	0.76
Other Liab	0.29	0.23	0.25	0.27	0.29	0.3	0.42	0.02	0.29	-0.25	0.26	0.32	0.32	0.34	0.36	0.21	0.17	0.37	0.27	0.32	0.32	0.22	0.16	0.34		-0.09
Other Assets	0.77	0.06	0.76	0.61	0.78	0.66	-0.1	0.5	0.74	0.83	0.75	0.44	0.78	0.73	0.44	0.68	0.36	0.71	0.74	0.64	0.78	0.25	0.89	0.76	-0.09

Click cells to compare fundamentals

Neurocrine Biosciences Account Relationship Matchups

Neurocrine Biosciences balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	1.7B	2.1B	2.4B	3.3B	3.7B	3.9B
Short Long Term Debt Total	412.3M	440.4M	262.9M	428.4M	455.1M	477.9M
Other Current Liab	147.1M	194.3M	292M	351.4M	397.7M	417.6M
Total Current Liabilities	186.5M	245.8M	537.7M	654.8M	507.7M	533.1M
Total Stockholder Equity	1.1B	1.4B	1.7B	2.2B	2.6B	2.7B
Property Plant And Equipment Net	127.4M	155.8M	145.6M	347.3M	592M	621.6M
Net Debt	(388.7M)	99.6M	169.4M	177.3M	222.1M	233.2M
Retained Earnings	(725.4M)	(635.8M)	(406.8M)	(157.1M)	29.2M	30.7M
Accounts Payable	39.4M	51.5M	67.3M	108.9M	110M	115.5M
Cash	801M	340.8M	262.9M	251.1M	233M	136.2M
Non Current Assets Total	718.5M	1.1B	915.2M	1.6B	2.0B	2.1B
Non Currrent Assets Other	6.4M	4.4M	25M	49.6M	755M	792.8M
Cash And Short Term Investments	801M	711.3M	989.3M	1.0B	1.1B	1.1B
Net Receivables	157.1M	185.5M	350M	439.3M	479.1M	503.1M
Common Stock Shares Outstanding	97.8M	97.9M	98.9M	101M	103.7M	63.6M
Liabilities And Stockholders Equity	1.7B	2.1B	2.4B	3.3B	3.7B	3.9B
Non Current Liabilities Total	422M	452.7M	123.2M	364.6M	621.3M	652.4M
Other Current Assets	30.1M	45.5M	79.1M	97.8M	112.1M	117.7M
Other Stockholder Equity	1.8B	2.0B	2.1B	2.4B	2.6B	2.7B
Total Liab	608.5M	698.5M	660.9M	1.0B	1.1B	1.2B
Property Plant And Equipment Gross	127.4M	155.8M	145.6M	430.3M	698.5M	733.4M
Total Current Assets	1.0B	972.8M	1.5B	1.6B	1.7B	1.8B
Accumulated Other Comprehensive Income	1.8M	(1.7M)	(7.9M)	7M	5.8M	6.1M
Short Term Debt	10.3M	16.5M	169.4M	170.1M	195.6M	205.4M
Intangible Assets	11.2M	12.5M	37.2M	35.5M	36.5M	38.3M
Short Term Investments	613.9M	370.5M	726.4M	780.5M	843.1M	885.3M
Other Liab	17.1M	9.7M	12.3M	29.7M	34.2M	24.8M
Other Assets	59.1M	674M	319.5M	330.9M	380.5M	399.6M
Long Term Debt	388.5M	408.8M	317.9M	335.1M	385.4M	404.6M
Property Plant Equipment	33.9M	41.9M	44.6M	58.6M	52.7M	55.4M
Current Deferred Revenue	(46.2M)	(10.3M)	(16.5M)	229.3M	263.7M	276.9M
Net Tangible Assets	228.1M	1.1B	1.4B	1.7B	1.9B	2.0B
Retained Earnings Total Equity	(1.1B)	(725.4M)	(635.8M)	(406.8M)	(366.1M)	(384.4M)
Capital Surpluse	1.8B	1.8B	2.0B	2.1B	2.4B	1.6B
Inventory	28M	30.5M	35.1M	38.3M	57.4M	60.3M
Non Current Liabilities Other	104.1M	117.6M	29.7M	10.3M	5.5M	5.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Neurocrine Stock Analysis

When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Neurocrine Historical Balance Sheet

Neurocrine Biosciences Inventory

60.27 Million

About Neurocrine Balance Sheet Analysis

Neurocrine Biosciences Balance Sheet Chart

Total Assets

Total Current Liabilities

Neurocrine Biosciences balance sheet Correlations

Neurocrine Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Neurocrine Biosciences balance sheet Accounts

Also Currently Popular

Additional Tools for Neurocrine Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Total Stockholder Equity	+ 0.99	Total Assets
Accounts Payable	+ 0.99	Total Assets
Non Current Assets Total	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Assets
Accounts Payable	+ 0.99	Other Current Liab

Retained Earnings	- 0.43	Short Long Term Debt Total
Cash	- 0.34	Net Debt
Common Stock Shares Outstanding	- 0.28	Retained Earnings
Other Liab	- 0.25	Cash
Other Assets	- 0.1	Net Debt
Other Assets	- 0.09	Other Liab